Effectiveness of Erythropoiesis-Stimulating Agent Therapy with Oral and Intravenous Iron Supplementation in Achieving Hemoglobin Targets in Stage 5 Chronic Kidney Disease Patients. JURNAL FARMASIMED (JFM), [S. l.], v. 9, n. 1, p. 499–507, 2026. DOI: 10.35451/jfm.v9i1.3691. Disponível em: https://ejournal.medistra.ac.id/index.php/JFM/article/view/3691. Acesso em: 1 nov. 2026.